{
    "nctId": "NCT01407770",
    "briefTitle": "Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer",
    "officialTitle": "Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cognitive Ability, General, Fatigue, Pain, Psychosocial Deprivation, Radiation Toxicity, Skin Abnormalities",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1000,
    "primaryOutcomeMeasure": "Occurrence of RT-induced early adverse skin reaction (EASR)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Female patients newly diagnosed with breast carcinoma including ductal carcinoma in situ (DCIS)\n\n  * Stage 0-IIIA disease\n* Status post-lumpectomy, -quadrantectomy, or -mastectomy\n* Plan to receive adjuvant radiation to the whole breast or chest wall and/or regional lymph nodes\n* No sites that cannot send blood/urine specimens to Wake Forest by overnight (next day) express shipping\n\nPATIENT CHARACTERISTICS:\n\n* \\*This stratum is closed as of April 25, 2012.\n* No patients who do not understand English and are unable to complete form with assistance\n\nPRIOR CONCURRENT THERAPY:\n\n* Total dose \\> 40 Gy, dose per fraction \\> 1.8 - 2.0 Gy, use of 2D, 3D-conformal, or intensity-modulated radiation therapy (IMRT) treatment techniques allowed; a daily fraction of 2.7 Gy to the whole breast is suggested for hypofractionated regimens\n* Concurrent and sequential boost techniques are allowed for both standard and hypofractionated regimens\n* Adjuvant hormonal therapy will be allowed prior to, during, and/or after radiotherapy (RT) at the discretion of a medical oncologist\n* Targeted therapies, such as Herceptin, will be allowed prior to, during, and/or after RT at the discretion of the medical oncologist\n* No prior radiation to the involved breast or chest wall\n* No concurrent chemotherapy\n* No patients who underwent breast reconstruction following mastectomy\n\n  * Placement of tissue expanders and implants are not allowed\n* No patients who have undergone MammoSite\u00ae or any other form of brachytherapy as well as those who will be treated with skin-sparing IMRT\n* Patients may not be concurrently enrolled in a protocol that involves treatment of the skin, i.e., applying lotions/moisturizers\n\n  * Protocols that do not involve treatment of the skin are allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}